Background A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome. Objectives To describe clinical characteristics, laboratory findings ...

Objectives The aim of this study was to evaluate, in a sample of patients with lupus, HRQoL and how it varies according to patients' perception of their health and their flare frequency. Methods An ...

1 Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen-Nürnberg and Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen, Germany 2 Deutsches Zentrum ...

7 Genetics and Population Health Division, Queensland Institute of Medical Research, Brsibane, Queensland, Australia 8 School of Population Health, University of Queensland, Herston, Queensland, ...

3 Centre for Public Health, Queens’ University Belfast, Belfast, UK 4 Department of Rheumatology, Altnagelvin Area Hospital, Londonderry, UK 5 Department of Rheumatology, Chapel Allerton Hospital, ...

2 Department of Rheumatology, University of Sydney Institute of Bone and Joint Research, Royal North Shore Hospital, St Leonards, New South Wales, Australia 3 Department of Rheumatology, Royal ...

Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies. The development of biological ...

Background: Randomised controlled trials (RCTs) evaluating the efficacy of antagonists to tumour necrosis factor α (TNFα) showed high response percentages in the groups treated with active drugs.

8 Faculty of Medicine, University of NSW, Sydney, New South Wales, Australia 9 Department of Rheumatology, St George Hospital, Sydney, New South Wales, Australia 10 Monash Department of Clinical ...

2 Institut d'Investigació Biomèdica de Bellvitge, Hospital Universitari de Bellvitge, Departament de Reumatologia, L'Hospitalet de Llobregat, Barcelona, Spain 3 Institute for Health Metrics and ...

Background Telitacicept (TACI-Fc fusion protein) is a novel BLyS (B-lymphocyte stimulator)/APRIL (a proliferation-inducing ligand) dual inhibitor, which has been approved in 2021 in China for the ...

2 Department of Rheumatology, Royal North Shore Hospital, Northern Clinical School, Sydney Medical School, University of Sydney, St Leonards, New South Wales, Australia 3 Institut d'Investigacio ...